- People
- Offices
- Capabilities
back- Capabilities
- Corporate, Finance and Investments
- back
- Corporate, Finance and Investments
- Overview
- Activist Defense
- Banking and Institutional Finance
- Capital Markets
- Construction and Procurement
- Corporate Governance
- Emerging Companies and Venture Capital
- Employee Benefits and Executive Compensation
- Energy and Infrastructure Projects
- Financial Restructuring
- Global Human Capital and Compliance
- Investment Funds and Asset Management
- Mergers and Acquisitions (M&A)
- Middle East and Islamic Finance and Investment
- Private Credit & Special Situations
- Private Equity
- Public Companies
- Real Estate
- Structured Finance and Securitization
- Tax
- Technology Transactions
- Government Matters
- back
- Government Matters
- Overview
- Antitrust
- Data, Privacy and Security
- Environmental, Health and Safety
- FDA and Life Sciences
- Government Advocacy and Public Policy
- Government Contracts
- Healthcare
- International Trade
- National Security and Corporate Espionage
- Securities Enforcement and Regulation
- Special Matters and Government Investigations
- Trial and Global Disputes
- back
- Trial and Global Disputes
- Overview
- Appellate, Constitutional and Administrative Law
- Bankruptcy and Insolvency Litigation
- Class Action Defense
- Commercial Litigation
- Construction and Engineering Disputes
- Corporate and Securities Litigation
- E-Discovery
- Intellectual Property
- International Arbitration and Litigation
- Labor and Employment
- Product Liability
- Professional Liability
- Toxic & Environmental Torts
- Industries / Issues
- back
- Industries / Issues
- Automotive, Transportation and Mobility
- Energy
- Financial Services
- Food and Beverage
- Higher Education
- Life Sciences and Healthcare
- Technology
- #MeToo
- Buy American
- COVID-19 Vaccine Rollout
- Crisis Management
- Environmental Agenda
- Environmental, Social and Governance (ESG)
- Focus on Women's Health
- Russia/Ukraine
- Special Purpose Acquisition Companies (SPACs)
- Careers
- News & Insights
- About
- Languages
Nikki Reeves
News 15 results
Recognition
June 8, 2022
Legal 500 United States 2022 Recognizes King & Spalding Practices and Lawyers Among the Top in the Nation
Recognition
June 1, 2022
Chambers USA 2022 Recognizes 188 K&S Lawyers and 75 K&S Practice Groups as Leaders in Their Fields
In the News · Source: JUVE
April 26, 2022
Wallaby Medical buys Phenox for 500 million euros
Recognition
October 5, 2021
LMG Life Sciences Recognizes King & Spalding With Multiple Rankings in its 2021 Guide
Events 22 results
Speaking Engagement
April 25, 2022
Nikki Reeves to Speak at Pharmaceutical Compliance Congress
Webinar
January 25, 2022
2021 Year in Review for Drug and Device Advertising and Promotion – Lessons Learned From FDA Enforcement Letters and Other Key Developments
Webinar
November 9, 2021
King & Spalding Pharmaceutical University 2021
Insights 29 results
Client Alert
July 28, 2022
A New Day (And A New Acronym) For OTC Drugs
Client Alert
March 28, 2022
AdvaMed Updates Code of Ethics on Interactions with HCPs: What’s the Impact on MedTech?
Article · Source: Chambers and Partners
March 21, 2022
Chambers Global Practice Guide: Pharmaceutical Advertising 2022
Client Alert
January 26, 2022
Spotlight on PFAS and Other Substances in Cosmetics Likely to Grow in 2022